ADC Therapeutics SA announced the appointment of Jennifer Herron as Chief Commercial Officer, effective November 4, 2019. In this newly created role, Ms. Herron will lead all global commercial activities as a member of the company’s senior management team. She is based in ADC Therapeutics’ New Jersey office. Most recently, Ms. Herron Ms. Herron served as Executive Vice President and Chief Commercial Officer at Immunogen, where she guided pre-commercialization planning for mirvetuximab soravtansine, the first folate receptor alpha-targeting ADC.